- Recruiting
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
Updated: Oct 24, 2022
MajesTEC1 study
A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)
Relapsed & Refractory Multiple Myeloma
The purpose of this study is evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
Study record NCT03145181 is Phase 1 part of this study and study record NCT04557098 is Phase 2 part of this study.
NCT03145181 - MajesTEC-1 - Parts 1-2
NCT04557098 - MajesTEC-1 - Part 3
Phase 2 - A study of teclistamab, a humanised BCMA x CD3 bispecific antibody in participants with relapsed or refractory multiple myeloma
Sponsor
Janssen Research & Development, LLC
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT03145181
Official Title: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
First Posted : September 21, 2020
Click here to see details on ClinicalTrials.gov
JNJ 64007957
Drug: Teclistamab
Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
PMID: 32956453; Blood Adv; Sep 2020
Click here to see details.
896 Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Immune Therapy for Multiple Myeloma
Hematology Disease Topics & Pathways:
Clinical Trials, Biological, Bispecific Antibody Therapy, Clinical Research, Plasma Cell Disorders, Diseases, Therapies, Immunotherapy, Lymphoid Malignancies
Monday, December 13, 2021: 6:30 PM
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.
Janssen will present the results from the Phase 1 and 2 MajesTEC-1 (Abstract #896) studies evaluating teclistamab (BCMAxCD3), an investigational, off-the-shelf, T-cell redirecting bispecific antibody in heavily pre-treated patients with multiple myeloma.
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
PMID: 34388396; Lancet; Aug 2021
Click here to see details
EHA2022 Oral Presentation
EHA 2022 - HYBRID - JUNE 9-17 - VIENNA
EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS
Click here to see Abstract details
June 28, 2022
International Myeloma Foundation
Subscribe to our channel: https://www.youtube.com/c/IMFMyeloma
June 28, 2022
International Myeloma Foundation
Subscribe to our channel: https://www.youtube.com/c/IMFMyeloma
ABSTRACTS & PRESENTATIONS
2022 ASCO ANNUAL MEETING - June 3-7, 2022 - McCormick Place, Chicago, IL - Hybrid Meeting
2022 ASCO Annual Meeting - Oral Abstract Session
Meeting: 2022 ASCO Annual Meeting - Session Type: Oral Abstract Session - Session Title: Hematologic Malignancies—Plasma Cell Dyscrasia - Track: Hematologic Malignancies - Sub Track: Hematologic Malignancies - Clinical Trial Registration Number: NCT04557098
Abstract#: 8007 - Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.
Click here to read abstract details
OAB-054 Comparative efficacy of teclistamab versus real-world physician’s choice of therapy in the prospective LocoMMotion study in patients with triple-class exposed relapsed/refractory multiple myeloma -Niels W.C.J. van de Donk
#IMS2022 - 19th International Myeloma Society Annual Meeting; August 25-27, 2022 - LA, California
https://www.myelomasociety.org/
- New York: Memorial Sloan-Kettering Cancer Center New York
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- North Carolina: Levine Cancer Institute Charlotte
- Alabama: University of Alabama at Birmingham
- Michigan: Barbara Ann Karmanos Cancer Institute Detroit
Locations
United States, Alabama
United States, California
United States, Connecticut
United States, Florida
United States, Georgia
United States, Michigan
United States, New York
United States, North Carolina
United States, Ohio
United States, Pennsylvania
Canada, Alberta
Canada, Ontario
Canada, Quebec
Europe
United Kingdom
France
Germany
Italy
Netherlands
Spain
Sweden
Belgium
Asia
China
RELATED POSTS
TECLISTAMAB STUDIES:
NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)
NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
TALQUETAMAB STUDIES:
NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma
TECLISTAMAB AND TALQUETAMAB STUDIES:
NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2